News & Media
- All
- News
- Press Releases
- Thought Leadership
- Webinars & Recent Talks
Recent Press
Center for Breakthrough Medicines Now Provides a Clinically Tested Adherent Manufacturing Platform for AAV Production
CBM is the Exclusive CDMO Provider of an iCellis 500-based
Adeno-Associated Virus (AAV) Adherent Platform developed by the Gene Therapy Program at the University of Pennsylvania
Cell One Partners and Center for Breakthrough Medicines Announce Strategic Partnership to Accelerate Cell and Gene Therapy Commercialization
Cell One Partners and Center for Breakthrough Medicines Announce Strategic Partnership to Accelerate Cell and Gene Therapy Commercialization
Center for Breakthrough Medicines, Nucleus Biologics, and Stoic Bio Announce Strategic Collaboration for Steady Supply of Quality Controlled Cell Culture Media to Expedite Development of Cell and Gene Therapies
Center for Breakthrough Medicines, Nucleus Biologics, and Stoic Bio Announce Strategic Collaboration for Steady Supply of Quality Controlled Cell Culture Media to Expedite Development of Cell and Gene Therapies
Center for Breakthrough Medicines Offers Pre-clinical Packages with Plasmids, Cell Line, and Pre-clinical Vector Manufacturing with Capacity Available Now
Center for Breakthrough Medicines Offers Pre-clinical Packages with Plasmids, Cell Line, and Pre-clinical Vector Manufacturing with Capacity Available Now
Center for Breakthrough Medicines and Virion Therapeutics Announce Strategic Partnership to Manufacture Virion’s Proprietary CD8+ T cell-based Clinical Development Programs for Infectious Diseases and Cancers
Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing critical challenges associated with the commercialization of cell and gene therapies, and Virion Therapeutics (Virion), a clinical-stage biotech company focu
Center for Breakthrough Medicines Launches Precision Plasmids™ Manufacturing to Accelerate Advanced Therapies into the Clinic
The Center for Breakthrough Medicines (CBM), a contract development, and manufacturing organization (CDMO) has launched their plasmid manufacturing offering, Precision PlasmidsTM to provide phase-appropriate plasmid on-demand to accelerate the path to clinic for cell and gene therapies.